Documents


Explore the latest documents from the company, including regulatory filings and corporate disclosures that offer insight into company performance and strategy. Use these resources to support informed investment decisions.
2026
Investor presentation
ROPEG expands across MPNs as 9M 2026 revenue reaches NTD 19.7B.
Earnings, Q3 FY2026
Revenue doubled YoY as operating income rose 168%.
Earnings, Q2 FY2026
Q2 2026 revenue rose 90% YoY, net income jumped 204%, and EPS hit a record NT$6.13.
Earnings, Q1 FY2026
Q1 2026 saw robust revenue and profit growth, with global expansion and R&D investments ongoing.
2025
Earnings, Q4 FY2025
2025 saw record revenue and profit, robust U.S. growth, and major expansion investments.
Earnings, Q3 FY2025
Net income surged 106% year-over-year on strong sales, with major investments in cell therapy and manufacturing.
Earnings, Q2 FY2025
H1 2025 saw revenue and net income surge, with strong cash reserves and key legal disputes resolved.
Earnings, Q1 FY2025
Q1 2025 delivered record revenue and profit growth, with robust cash flow and global expansion.
2024
Earnings, Q4 FY2024
Returned to profitability with record revenue, strong US sales, and major R&D and capital investments.
Earnings, Q3 FY2024
Revenue surged and net income rebounded sharply, supported by global expansion and R&D investment.
Earnings, Q2 FY2024
Revenue and net income soared in H1 2024, driven by robust sales and global expansion.
Earnings, Q1 FY2024
2023
Earnings, Q4 FY2023
Earnings, Q3 FY2023
Earnings, Q2 FY2023
Earnings, Q1 FY2023